Abbott Laboratories vs TORM plc — how do they compare? Abbott Laboratories trades at $111.08 (market cap $187.95B), while TORM plc trades at $28.78 (market cap $2.93B). The key difference: Abbott Laboratories is far larger — about 64.1× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.
| ABT | TRMD | |
|---|---|---|
Market Cap | $187.95B | $2.93B |
Sector | Health | Technology |
52-Week High | $136.62 | $34.87 |
52-Week Low | $82.57 | $18.77 |
Enterprise Value | $214.96B | $3.82B |
Dividend Yield | 2.32% | 9.77% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
TRMD trades at $28.84, down 1.2% with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $1.34B revenue, $285.3M net income, and a 24.41% net margin. Recent earnings show mixed performance with Q2 2026 expectations at $3.41 EPS. Analyst consensus remains unanimously bullish with 3 buy ratings. Technical indicators show oversold conditions with RSI at 24.63, while support levels cluster around $28.
The stock presents a value opportunity with attractive valuation multiples (P/E 8.4, EV/EBITDA 5.95) and strong profitability metrics (ROE 15.62%). Near-term catalysts include Q2 2026 earnings and the $0.70 dividend payment in June. Key risks include earnings volatility, tanker market cyclicality, and negative cash flow trends. Institutional ownership stability and positive analyst coverage support the bullish case despite technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →